Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation digital software solutions and novel, proprietary medication decision support tools, today announced that its subsidiary, SinfoníaRx, has launched its medication therapy management (“MTM”) solutions and services for Medicaid beneficiaries in Florida and Virginia under an agreement with a major behavioral health payer.
“MTM programs are a central part of the Medicare prescription drug benefit; however, they are not common in Medicaid. This program utilizes best practices from our experience, and it goes a step further to provide specialized support for Medicaid beneficiaries who suffer from behavioral health-related problems,” said Kevin P. Boesen, PharmD, CEO of SinfoníaRx. “This includes assistance for patients who may need extra help managing both their mental and physical health. In addition to our traditional MTM services, we will provide pain management and opioid monitoring, which will fill an important need.”
A significant percentage of Medicaid beneficiaries have behavioral health conditions and a growing number have opioid addictions. According to a study by the Kaiser Family Foundation, Medicaid covers three in ten non-elderly adults with opioid addiction. This offering will help manage these issues through a number of methods, including monitoring for medication adherence, uncoordinated care, and the use of multiple prescribers or multiple community pharmacies.
The innovative MTM program includes weekly medication risk assessments, ongoing medication surveillance, and personalized consultation services by highly trained clinical pharmacy teams. The medication assessments and surveillance incorporate proprietary clinical algorithms to identify patients at risk for medication-related problems. “We are pleased to be part of the solution for behavioral health companies to better manage and to help prevent medication-related problems,” said Calvin H. Knowlton, PhD, Chairman and CEO of TRHC.